<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">tiblj</journal-id><journal-title-group><journal-title xml:lang="ru">Туберкулез и болезни легких</journal-title><trans-title-group xml:lang="en"><trans-title>Tuberculosis and Lung Diseases</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2075-1230</issn><issn pub-type="epub">2542-1506</issn><publisher><publisher-name>Медицинские знания и технологии</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21292/2075-1230-2021-99-8-54-60</article-id><article-id custom-type="elpub" pub-id-type="custom">tiblj-1566</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОР</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW</subject></subj-group></article-categories><title-group><article-title>Лекарственно-индуцированные поражения легких противоопухолевыми препаратами: распространенность, некоторые препараты и механизмы их воздействия. Часть 2</article-title><trans-title-group xml:lang="en"><trans-title>Lung Injury Induced by Antitumor Drugs: Prevalence, Certain Drugs and Their Mechanisms of Action. Part 2</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Орлова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Orlova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Орлова Наталья Васильевна, доктор медицинских наук, профессор</p><p>117997, Москва, ул. Островитянова, д. 1</p><p>Тел.: +7 (495) 674-48-68. </p></bio><bio xml:lang="en"><p>Orlova Natalia V., Doctor of Medical Sciences, Professor. 1, Ostrovityanova St., Moscow, 117997.</p><p>Phone: +7 (495) 674-48-68</p></bio><email xlink:type="simple">vrach315@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Остроумова</surname><given-names>О. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Ostroumova</surname><given-names>O. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Остроумова Ольга Дмитриевна, доктор медицинских наук, профессор, заведующая кафедрой терапии и полиморбидной патологии</p><p>125993, Москва, ул. Баррикадная, д. 2/1, стр. 1</p><p>Тел.: +7 (495) 945-11-28</p></bio><bio xml:lang="en"><p>Ostoumova Olga D., Doctor o f Medical Sciences, Professor, Head of Department of Therapy and Polymorbid Pathology</p><p>2/1, Build. 1. Barrikadnaya St., Moscow, 125993</p><p>Phone: +7 (495) 945-11-28.</p></bio><email xlink:type="simple">ostroumova.olga@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ших</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shikh</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ших Евгения Валерьевна, доктор медицинских наук, профессор, заведующая кафедрой клинической фармакологии и пропедевтикивнутренних болезней, директор Института профессионального образования</p><p>119991, Москва, ул. Трубецкая, д. 8, стр. 2</p><p>Тел.: +7 (495) 609-19-91</p></bio><bio xml:lang="en"><p>Shikh Evgeniya V., Doctor of Medical Sciences, Professor, Head of Department of Clinical Pharmacology and Propedeutics o f Internal Diseases, Director of Professional Education Institut</p><p>8, Bd. 2, Trubetskaya St., Moscow, 119991</p></bio><email xlink:type="simple">chih@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смердин</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Smerdin</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Смердин Сергей Викторович, доктор медицинских наук, профессор, главный врач</p><p>141132, Московская область, Щелковский район, д. Сукманиха, влад. 1Б</p><p>Тел.: +7 (499) 978-02-43.</p></bio><bio xml:lang="en"><p>Smerdin Sergey V., Doctor o f Medical Sciences, Professor, Chief Physician</p><p>1b, Village o f Sukmanikha, Schelkovsky Raion, Moscow Region, 141132</p><p>Phone: +7 (499) 978-02-43. </p></bio><email xlink:type="simple">smerdin_030@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Реброва</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Rebrova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Реброва Екатерина Владиславовна, кандидат медицинских наук,доцент кафедры клинической фармакологии и пропедевтики внутренних болезней</p><p>119991, Москва, ул. Трубецкая, д. 8, стр. 2</p><p>Тел.: +7 (495) 609-14-00</p></bio><bio xml:lang="en"><p>Rebrova Ekaterina V., Candidate of Medical Sciences, Associate Professor of Department of Clinical Pharmacology and Propedeutics of Internal Diseases</p><p>Phone: +7 (495) 609-14-00.</p><p>8, Bd. 2, Trubetskaya St., Moscow, 119991</p></bio><email xlink:type="simple">katrina1987@rambler.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дё</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Dyo</surname><given-names>V. А.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дё Валерия Анатольевна, ординатор кафедры терапии и полиморбидной патологии</p><p>125993, Москва, ул. Баррикадная, д. 2/1, стр. 1</p><p>Тел.: +7 (495) 945-11-28</p></bio><bio xml:lang="en"><p>Dyo Valeria A., Resident of Department o f Therapy and Polymorbid Pathology. </p><p>2/1, Build. 1. Barrikadnaya St., Moscow, 125993</p><p>Phone: +7 (495) 945-11-28</p></bio><email xlink:type="simple">devaleria97@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУВО «РНИМУ им. Н. И. Пирогова» МЗ РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» МЗ РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian Medical Academy of On-going Professional Education</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I. M. Sechenov First Moscow State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ГБУЗ МО «Московский областной клинический противотуберкулезный диспансер»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Regional Clinical TB Dispensary</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>10</day><month>09</month><year>2021</year></pub-date><volume>99</volume><issue>8</issue><fpage>54</fpage><lpage>60</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Орлова Н.В., Остроумова О.Д., Ших Е.В., Смердин С.В., Реброва Е.В., Дё В.А., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Орлова Н.В., Остроумова О.Д., Ших Е.В., Смердин С.В., Реброва Е.В., Дё В.А.</copyright-holder><copyright-holder xml:lang="en">Orlova N.V., Ostroumova O.D., Shikh E.V., Smerdin S.V., Rebrova E.V., Dyo V.А.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.tibl-journal.com/jour/article/view/1566">https://www.tibl-journal.com/jour/article/view/1566</self-uri><abstract><p>Проанализировано 49 источников литературы о нежелательных лекарственных реакциях, возникающих при терапии противоопухолевыми препаратами. Представлены данные о пневмотоксичности и ее клинических проявлениях для таких противоопухолевых препаратов, как блеомицин, бусульфан, циклофосфамид, хлорамбуцил, метотрексат, производные нитрозомочевины, таксаны, при этом механизмы развития поражения легких не совсем ясны, что требует дальнейших исследований. Для профилактики лекарственно-индуцированного поражения легких необходима информированность практикующих врачей разных специальностей, прежде всего терапевтов, ревматологов, клинических иммунологов, пульмонологов, фтизиатров, онкологов, ввиду неспецифичности симптомов лекарственно-индуцированного поражения легких и применения противоопухолевых лекарственных средств не только при развитии онкологических заболеваний.</p></abstract><trans-abstract xml:lang="en"><p>The article analyzes 49 publications on adverse drug reactions occurring during therapy with antitumor drugs. It presents data on pneumotoxicity and its clinical manifestations for such anticancer drugs as bleomycin, busulfan, cyclophosphamide, chlorambucil, methotrexate, nitrosourea derivatives, and taxanes, while the mechanisms of lung injury are not entirely clear and require further research. The prevention of drug-induced lung injury requires raising awareness among practicing physicians of different specialties, primarily general practitioners, rheumatologists, clinical immunologists, pulmonologists, phthisiologists, and oncologists due to non-specific manifestations of drug-induced lung injury and the use of antitumor drugs for other diseases apart from cancer.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>лекарственно-индуцированные поражения легких</kwd><kwd>противоопухолевые препараты</kwd><kwd>пневмотоксичность</kwd><kwd>нежелательные &#13;
лекарственные реакции</kwd></kwd-group><kwd-group xml:lang="en"><kwd>drug-induced lung injury</kwd><kwd>antineoplastic drugs</kwd><kwd>pneumotoxicity</kwd><kwd>adverse drug reactions</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ahya V. N. Noninfectious Acute lung injury syndromes early after hematopoietic stem cell transplantation // Clin. Chest Med. - 2017. - № 38 (4). - Р. 595.</mixed-citation><mixed-citation xml:lang="en">Ahya V. N. Noninfectious Acute lung injury syndromes early after hematopoietic stem cell transplantation. Clin. Chest Med., 2017, no. 38 (4), pp. 595.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Alessandrino E. P., Bernasconi P., Colombo A. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies // Bone Marrow Transplant. - 2000. - № 25. - Р. 309.</mixed-citation><mixed-citation xml:lang="en">Alessandrino E. P., Bernasconi P., Colombo A. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow transplant., 2000, no. 25, pp. 309.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Becker C. D., Gil J., Padilla M. L. Idiopathic pleuroparenchymal fibroelastosis: an unrecognized or misdiagnosed entity? // Mod. Pathol. - 2008. - № 21. - Р. 784.</mixed-citation><mixed-citation xml:lang="en">Becker C. D., Gil J., Padilla M. L. Idiopathic pleuroparenchymal fibroelastosis: an unrecognized or misdiagnosed entity? Mod. Pathol., 2008, no. 21, pp. 784.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bertrand M., Wemeau-Stervinou L., Gauthier S. New toxicity of fotemustine: diffuse interstitial lung disease // Ann. Dermatol. Venereol. - 2012. - № 139. - Р 277.</mixed-citation><mixed-citation xml:lang="en">Bertrand M., Wemeau-Stervinou L., Gauthier S. New toxicity of fotemustine: diffuse interstitial lung disease. Ann. Dermatol. Venereol. 2012, no. 139, pp. 277.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Beynat-Mouterde C., Beltramo G., Lezmi G. Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents // Eur. Respir. J. - 2014. - № 44. - Р 523.</mixed-citation><mixed-citation xml:lang="en">Beynat-Mouterde C., Beltramo G., Lezmi G. Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents. Eur Respir J., 2014, no. 44, pp. 523.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bielopolski D., Evron E., Moreh-Rahav O. Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature // J. Chemother. - 2017. - № 29. - Р. 113.</mixed-citation><mixed-citation xml:lang="en">Bielopolski D., Evron E., Moreh-Rahav O. Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature. J. Chemother., 2017, no. 29, pp. 113.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bonniaud P, Georges M., Favrolt N., Camus P. Drug-induced interstitial lung diseases // Rev. Prat. - 2014. - № 64. - P. 951.</mixed-citation><mixed-citation xml:lang="en">Bonniaud P., Georges M., Favrolt N., Camus P. Drug-induced interstitial lung diseases. Rev. Prat., 2014, no. 64, pp. 951.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Bredeson C., LeRademacher J., Kato K. et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation // Blood. - 2013. - № 122. - Р. 3871.</mixed-citation><mixed-citation xml:lang="en">Bredeson C., LeRademacher J., Kato K. et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood, 2013, no. 122, pp. 3871.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Brockstein B. E., Smiley C., Al-Sadir J., Williams S. F. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors // Bone Marrow Transplant. - 2000. - № 25. - Р. 885.</mixed-citation><mixed-citation xml:lang="en">Brockstein B. E., Smiley C., Al-Sadir J., Williams S. F. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors. Bone Marrow Transplant., 2000, no. 25, pp. 885.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Camus P. Interstitial lung disease from drugs, biologics, and radiation. Interstitial Lung Disease, 5th. Eds.: Schwarz M., King T. E. Jr. - People’s Medical Publishing House-USA, Shelton CT. - 2011. - 637 p.</mixed-citation><mixed-citation xml:lang="en">Camus P. Interstitial lung disease from drugs, biologics, and radiation. Interstitial Lung Disease, 5th. Eds.: Schwarz M., King T.E.Jr. People’s Medical Publishing House-USA, Shelton CT. 2011, 637 p.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Camus P. The drug-induced respiratory disease website. www.pneumotox.com (Accessed on June 23, 2017).</mixed-citation><mixed-citation xml:lang="en">Camus P. The drug-induced respiratory disease website. www.pneumotox.com (Accessed on June 23, 2017).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Camus P., von der Thusen J., Hansell D. M., Colby T. V. Pleuroparenchymal fibroelastosis: one more walk on the wild side of drugs? // Eur. Respir. J. - 2014. - № 44. - Р. 289.</mixed-citation><mixed-citation xml:lang="en">Camus P., von der Thusen J., Hansell D.M., Colby T.V. Pleuroparenchymal fibroelastosis: one more walk on the wild side of drugs? Eur. Respir. J., 2014, no. 44, pp. 289.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Cao T. M., Negrin R. S., Stockerl-Goldstein K. E., Johnston L. J., Shizuru J. A., Taylor T. L., Rizk N. W., Wong R. M., Blume K. G., Hu W. W. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation // Biol. Blood Marrow Transplant. - 2000. - № 6 (4). - Р. 387-394.</mixed-citation><mixed-citation xml:lang="en">Cao T. M., Negrin R.S., Stockerl-Goldstein K.E., Johnston L.J., Shizuru J.A., Taylor T.L., Rizk N.W., Wong R.M., Blume K.G., Hu W.W. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol. Blood Marrow Transplant., 2000, no. 6 (4), pp. 387-394.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Catovsky D., Richards S., Matutes E. et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial // Lancet. - 2007. - № 370. - Р. 230.</mixed-citation><mixed-citation xml:lang="en">Catovsky D., Richards S., Matutes E. et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet, 2007, no. 370, pp. 230.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Copelan E. A., Hamilton B. K., Avalos B. et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI // Blood. - 2013. - № 122. - Р. 3863.</mixed-citation><mixed-citation xml:lang="en">Copelan E. A., Hamilton B. K., Avalos B. et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood, 2013, no. 122, pp. 3863.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Dhokarh R., Li G., Schmickl C. N., Kashyap R., Assudani J., Limper A. H., Gajic O. Drug-associated acute lung injury: a population-based cohort study // Chest. - 2012. - P. 845.</mixed-citation><mixed-citation xml:lang="en">Dhokarh R., Li G., Schmickl C. N., Kashyap R., Assudani J., Limper A.H., Gajic O. Drug-associated acute lung injury: a population-based cohort study. Chest, 2012, pp. 845.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Dormann H., Muth-Selbach U., Krebs S., Criegee-Rieck M., Tegeder I., Schneider H. T., Hahn E. G., Levy M., Brune K., Geisslinger G. Incidence and costs of adverse drug reactions during hospitalization // Drug Safety. - 2000. - № 22 (2). - P. 161-168.</mixed-citation><mixed-citation xml:lang="en">Dormann H., Muth-Selbach U., Krebs S., Criegee-Rieck M., Tegeder I., Schneider H. T., Hahn E. G., Levy M., Brune K., Geisslinger G. Incidence and costs of adverse drug reactions during hospitalization. Drug Safety, 2000, no. 22 (2), pp. 161-168.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Fernandez H. F., Tran H. T., Albrecht F. et al. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation // Biol. Blood Marrow Transplant. - 2002. - № 8. - Р. 486.</mixed-citation><mixed-citation xml:lang="en">Fernandez H. F., Tran H. T., Albrecht F. et al. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant diseaseundergoing stem cell transplantation. Biol. Blood Marrow Transplant., 2002, no. 8, pp. 486.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Frankel S. K., Cool C. D., Lynch D. A., Brown K. K. Idiopathic pleuroparenchymal fibroelastosis: description of a novel clinicopathologic entity // Chest. - 2004. - № 126. - 2007.</mixed-citation><mixed-citation xml:lang="en">Frankel S. K., Cool C. D., Lynch D. A., Brown K. K. Idiopathic pleuroparenchymal fibroelastosis: description of a novel clinicopathologic entity. Chest, 2004, no. 126, 2007.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Fujimoto D., Kato R., Morimoto T., Shimizu R., Sato Yu., Kogo M., Ito J., Teraoka Sh., Nagata K., Nakagawa A., Otsuka K., Tomii K. Characteristics and prognostic impact of pneumonitis during systemic anti-cancer therapy in patients with advanced non-small-cell lung cancer // PLoS One. - 2016. - P. 11.</mixed-citation><mixed-citation xml:lang="en">Fujimoto D., Kato R., Morimoto T., Shimizu R., Sato Yu., Kogo M., Ito J., Teraoka Sh., Nagata K., Nakagawa A., Otsuka K., Tomii K. Characteristics and prognostic impact of pneumonitis during systemic anti-cancer therapy in patients with advanced non-small-cell lung cancer. PLoS One, 2016, pp. 11.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Grove M. L., Hassell A. B., Hay E. M., Shadforth M. F. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice // QJM. - 2001. - № 94. - Р. 309.</mixed-citation><mixed-citation xml:lang="en">Grove M. L., Hassell A. B., Hay E. M., Shadforth M. F. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. QJM, 2001, no. 94, pp. 309.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Hanel M., Kroger N., Sonnenberg S., et al. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma // Ann. Hematol. - 2002. - № 81. - Р. 96.</mixed-citation><mixed-citation xml:lang="en">Hanel M., Kroger N., Sonnenberg S., et al. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann. Hematol., 2002, no. 81, pp. 96.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Ho V. T., Weller E., Lee S. J., Alyea E. P., Antin J. H., Soiffer R. J. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation // Biol. Blood Marrow Transplant. - 2001. - № 7(4). - P. 223-229.</mixed-citation><mixed-citation xml:lang="en">Ho V. T., Weller E., Lee S.J., Alyea E. P., Antin J.H., Soiffer R. J. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant., 2001, no. 7 (4), pp. 223-229.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Imokawa S., Colby T. V., Leslie K. O., Helmers R. A. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients // Eur. Respir. J. - 2000. - № 15. - Р. 373-381.</mixed-citation><mixed-citation xml:lang="en">Imokawa S., Colby T.V., Leslie K. O., Helmers R. A. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur.Respir. J., 2000, no. 15, pp. 373-381.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kalambokis G., Stefanou D., Arkoumani E., Tsianos E. Bronchiolitis obliterans organizing pneumonia following chlorambucil treatment for chronic lymphocytic leukemia // Eur. J. Haematol. - 2004. - № 73. - Р. 139.</mixed-citation><mixed-citation xml:lang="en">Kalambokis G., Stefanou D., Arkoumani E., Tsianos E. Bronchiolitis obliterans organizing pneumonia following chlorambucil treatment for chronic lymphocytic leukemia. Eur. J. Haematol., 2004, no. 73, pp. 139.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Kim H. Y., Hwang J. H., Chang Y.-W., Moon J. Y. Pulmonary Complications of Antineoplastic Agents: Era of Targeted Therapy // ECR. - 2013. - № 1230. - P. 1-30.</mixed-citation><mixed-citation xml:lang="en">Kim H.Y., Hwang J. H., Chang Y. W., Moon J. Y. Pulmonary Complications of Antineoplastic Agents: Era of Targeted Therapy. ECR, 2013, no. 1230, pp. 1-30.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Kinder A. J., Hassell A. B., Brand J., Brownfield A., Grove M., Shadforth M. F. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions // Rheumatology (Oxford). - 2005. - № 44. - Р. 61-66.</mixed-citation><mixed-citation xml:lang="en">Kinder A. J., Hassell A. B., Brand J., Brownfield A., Grove M., Shadforth M.F. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford), 2005, no. 44, pp. 61-66.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Kreisman H., Wolkove N. Pulmonary toxicity of antineoplastic therapy // Semin Oncol. - 1992. - № 19. - P. 20.</mixed-citation><mixed-citation xml:lang="en">Kreisman H., Wolkove N. Pulmonary toxicity of antineoplastic therapy. Semin Oncol., 1992, no. 19, pp. 20.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Kubo K., Azuma A., Kanazawa M., Kameda H., Kusumoto M., Genma A., Saijo Y., Sakai F., Sugiyama Y., Tatsumi K., Dohi M., Tokuda H., Hashimoto S., Hattori N., Hanaoka M., Fukuda Y. Consensus statement for the diagnosis and treatment of drug-induced lung injuries // Respir. Invest. - 2013. - № 51. - P. 260-277.</mixed-citation><mixed-citation xml:lang="en">Kubo K., Azuma A., Kanazawa M., Kameda H., Kusumoto M., Genma A., Saijo Y., Sakai F., Sugiyama Y., Tatsumi K., Dohi M., Tokuda H., Hashimoto S., Hattori N., Hanaoka M., Fukuda Y. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir. Invest., 2013, no. 51, pp. 260-277.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Le Guillou F., Dominique S., Dubruille V. et al. Acute respiratory distress syndrome due to pneum onitis following intrathecal methotrexate administration // Rev. Mal. Respir. - 2003. - № 20. - Р. 273.</mixed-citation><mixed-citation xml:lang="en">Le Guillou F., Dominique S., Dubruille V. et al. Acute respiratory distress syndrome due to pneumonitis following intrathecal methotrexate administration. Rev. Mai. Respir., 2003, no. 20, pp. 273.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Lee Yoon S. Y., Kim K. H., Lee N., Kim H. Y., Hwang J. H., Jong-Ho Won J.-H. Pulmonary toxicities of molecular targeted antineoplastic agents: a single-center 10-year experience // Korean J. Intern. Med. - 2021. - P. 1-10.</mixed-citation><mixed-citation xml:lang="en">Lee M. Y., Yoon S. Y., Kim K. H., Lee N., Kim H. Y., Hwang J. H., Jong-Ho Won J.H. Pulmonary toxicities of molecular targeted antineoplastic agents: a single-center 10-year experience. Korean J. Intern. Med., 2021, pp. 1-10.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Meadors M., Floyd J., Perry M. C. Pulmonary toxicity of chemotherapy // Semin Oncol. - 2006. - № 33. - Р. 98.</mixed-citation><mixed-citation xml:lang="en">Meadors M., Floyd J., Perry M. C. Pulmonary toxicity of chemotherapy. Semin Oncol., 2006, no. 33, pp. 98.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Orchard P. J., Fasth A. L., Le Rademacher J. et al. Hematopoietic stem cell transplantation for infantile osteopetrosis // Blood. - 2015. - № 126. - Р. 270.</mixed-citation><mixed-citation xml:lang="en">Orchard P. J., Fasth A. L., Le Rademacher J. et al. Hematopoietic stem cell transplantation for infantile osteopetrosis. Blood, 2015, no. 126, pp. 270.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">O’Sullivan J. M., Huddart R. A., Norman A. R., Nicholls J., Dearnaley D. P., Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours // Ann. Oncology. - 2003. - Vol. 14, № 1. - Р. 91-96.</mixed-citation><mixed-citation xml:lang="en">O’Sullivan J. M., Huddart R. A., Norman A. R., Nicholls J., Dearnaley D. P., Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann. Oncology, 2003, vol. 14, no. 1, pp. 91-96.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Ozkan М., Dweik R. A. Drug-induced lung disease // Cleveland Clin. J. Med. - 2001. - № 68 (9). - Р. 782-795.</mixed-citation><mixed-citation xml:lang="en">Ozkan М., Dweik R.A. Drug-induced lung disease. Cleveland Clin. J. Med., 2001, no. 68 (9), pp. 782-795.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Panoskaltsis-Mortari A., Griese M., Madtes D. K. et al. An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome // Am. J. Respir. Crit. Care Med. - 2011. - № 183. - Р. 1262.</mixed-citation><mixed-citation xml:lang="en">Panoskaltsis-Mortari A., Griese M., Madtes D. K. et al. An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am. J. Respir. Crit. Care Med., 2011, no. 183, pp. 1262.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Peters C., Schrappe M., von Stackelberg A. et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial // J. Clin. Oncol. - 2015. - № 33. - Р. 1265.</mixed-citation><mixed-citation xml:lang="en">Peters C., Schrappe M., von Stackelberg A. et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. J. Clin. Oncol., 2015, no. 33, pp. 1265.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Remesh A. Toxicities of anticancer drugs and its management // Int. J. Basic Clin. Pharmacol. - 2012. - № 1. - P. 2-12.</mixed-citation><mixed-citation xml:lang="en">Remesh A. Toxicities of anticancer drugs and its management. Int. J. Basic Clin. Pharmacol., 2012, no. 1, pp. 2-12.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Robert C., Ribas A., Wolchok J. D., Hodi F. S., Hamid O., Kefford R., Weber J. S., Joshua A. M., Hwu W-J., Gangadhar T. C., Patnaik A., Dronca R., Zarour H., Joseph R. W., Boasberg P., Chmielowski B., Mateus Ch., Postow M. A., Gergich K., Elassaiss-Schaap J., Li X. N., Iannone R., Ebbinghaus Sc. W., Kang S. P, Daud A. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial // Lancet. - 2014. - № 9948. - P. 1109-1117.</mixed-citation><mixed-citation xml:lang="en">Robert C., Ribas A., Wolchok J. D., Hodi F. S., Hamid O., Kefford R., Weber J. S., Joshua A. M., Hwu W-J., Gangadhar T. C., Patnaik A., Dronca R., Zarour H., Joseph R.W., Boasberg P., Chmielowski B., Mateus Ch., Postow M.A., Gergich K., Elassaiss-Schaap J., Li X.N., Iannone R., Ebbinghaus Sc. W., Kang S. P., Daud A. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, 2014, no. 9948, pp. 1109-1117.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Rosenow 3rd E. C. Drug-induced pulmonary disease // Dis. Mon. - 1994. - № 40. - Р. 253-310.</mixed-citation><mixed-citation xml:lang="en">Rosenow 3rd E. C. Drug-induced pulmonary disease. Dis. Mon., 1994, no. 40, pp. 253-310.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Salliot C., van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research // Ann. Rheum Dis. - 2009. - № 68. - Р. 1100.</mixed-citation><mixed-citation xml:lang="en">Salliot C., van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann. Rheum Dis., 2009, no. 68, pp. 1100.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Saravanan V., Kelly C. Drug-related pulmonary problems in patients with rheumatoid arthritis // Rheumatology (Oxford). - 2006. - № 45. - Р. 787.</mixed-citation><mixed-citation xml:lang="en">Saravanan V., Kelly C. Drug-related pulmonary problems in patients with rheumatoid arthritis. Rheumatology (Oxford), 2006, no. 45, pp. 787.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Segura A., Yuste A., Cercos A. et al. Pulmonary fibrosis induced by cyclophosphamide // Ann. Pharmacother. - 2001. - № 35. - Р. 894.</mixed-citation><mixed-citation xml:lang="en">Segura A., Yuste A., Cercos A. et al. Pulm onary fibrosis induced by cyclophosphamide. Ann. Pharmacother., 2001, no. 35, pp. 894.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Shafqat H., Olszewski A. J. Chlorambucil-induced acute interstitial pneumonitis // Case Rep. Hematol. - 2014. - е575417.</mixed-citation><mixed-citation xml:lang="en">Shafqat H., Olszewski A. J. Chlorambucil-induced acute interstitial pneumonitis. Case Rep. Hematol., 2014, е575417.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Sleijfer S. Bleomycin-induced pneumonitis // Chest. - 2001. - № 120. - Р. 617.</mixed-citation><mixed-citation xml:lang="en">Sleijfer S. Bleomycin-induced pneumonitis. Chest, 2001, no. 120, pp. 617.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Ulrickson M., Aldridge J., Kim H. T. et al. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience // Biol. Blood. Marrow Transplant. - 2009. - № 15. - Р. 1447.</mixed-citation><mixed-citation xml:lang="en">Ulrickson M., Aldridge J., Kim H. T. et al. Busulfan and yclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. Biol. Blood Marrow Transplant., 2009, no. 15, pp. 1447.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Wei-I L., Hissaria P. Drug-Induced Interstitial Lung Disease // Indian J. Rheumatology. - 2021. - № 21. - P. 19-26.</mixed-citation><mixed-citation xml:lang="en">Wei-I L., Hissaria P. Drug-Induced Interstitial Lung Disease. Indian J. Rheumatology, 2021, no. 21, pp. 19-26.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Zarogoulidis P., Chatzaki E., Porpodis K., Domvri K., Hohenforst-Schmidt W., Goldberg E. P, Karamanos N., Zarogoulidis K. Inhaled chemotherapy in lung cancer: Future concept of nanomedicine // Int. J. Nanomed. - 2012. - № 7. - Р. 1551-1572.</mixed-citation><mixed-citation xml:lang="en">Zarogoulidis P, Chatzaki E., Porpodis K., Domvri K., Hohenforst-Schmidt W., Goldberg E. P., Karamanos N., Zarogoulidis K. Inhaled chemotherapy in lung cancer: Future concept of nanomedicine. Int. J. Nanomed, 2012, no. 7, pp. 1551-1572.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Zucca E., Conconi A., Laszlo D. et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study // J. Clin. Oncol. - 2013. - № 31. - Р. 565.</mixed-citation><mixed-citation xml:lang="en">Zucca E., Conconi A., Laszlo D. et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J. Clin. Oncol., 2013, no. 31, pp. 565.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
